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ABSTRACT 
 
MEGHAN E JONES: The role of brain interleukin-1 in stress-enhanced fear learning 
(Under the direction of Donald T. Lysle) 
Post-Traumatic Stress Disorder (PTSD) has been shown to be associated with pro-
inflammatory markers, including elevated plasma levels of interleukin-1β (IL-1β). However, 
the precise role of neuroinflammation and central immune signaling on the development of 
this debilitating psychological disorder is not known. Here, we employed stress-enhanced 
fear learning, an animal model of the disorder, to examine the role of central IL-1β in PTSD. 
The results show that the severe stressor in SEFL induces a time-dependent increase in IL-1β 
immunoreactivity and mRNA expression within the dentate gyrus of the dorsal hippocampus. 
There was no increase in IL-1β in the basolateral amygdala or the perirhinal cortex. 
Moreover, blocking the action of IL-1β following the severe stressor with IL-1 receptor 
antagonist (10 µg, i.c.v., 24 and 48 hours after the stressor) prevented the development of 
SEFL. To provide further support for the role of IL-1β in the development of SEFL, we show 
that systemic morphine, a treatment which is known to reduce both PTSD and SEFL, also 
reduces IL-1β expression in the dorsal hippocampus induced by the severe stressor. These 
studies provide the first evidence that IL-1 is involved SEFL, and suggest that IL-1 signaling 
in the brain may play a critical role in the development of PTSD.  
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CHAPTER I 
INTRODUCTION 
 
Psychopathology and disease states involving depression and anxiety have been 
associated with pro-inflammatory markers in both human populations and preclinical rodent 
models (Spivak, Shohat et al. 1997; Gill, Saligan et al. 2009; Stepanichev, Dygalo et al. 
2014). However, the precise role of neuroinflammation and immune signaling in this context 
remains unclear. Cytokines, traditionally known for their role in the periphery in defense 
against infection and disease, have recently been revealed as important signaling molecules 
in neuro-glial communication pathways. For example, transgenic mouse lines deficient in 
central signaling involving pro-inflammtaory cytokines, such as interleukin-1β (IL-1β) or 
tumor necrosis factor-α (TNF-α), consistently exhibit altered anxiety behavior in the elevated 
plus maze or open field test. (Silverman, Macdougall et al. 2007; Koo and Duman 2009). 
Further, an infusion of IL-1β into the lateral ventricle is sufficient to induce anxiety like 
behavior in the elevated plus maze (Koo and Duman 2009). Thus, the immune system has the 
capability to modulate central signaling and play an important role in behavior and the 
development of psychopathology.   
IL-1β has been implicated in a wide range of behaviors. Early studies implicated this 
cytokine in a specific behavioral complex, sickness behavior, which is characterized by sleep 
disorders, anxiety, and diminished social interactions (Dantzer 2001). Importantly, IL-1β 
signaling is also critical for normal learning and memory processing. Accumulating evidence 
suggests that while a basal level of IL-1β is required for memory formation, both excessive 
  
and insufficient amounts of IL-1β impair memory formation (Goshen, Kreisel et al. 
2007). Further, converging evidence suggests that many of the neurobiological parallels 
between a disease state and a state of stress, both of which are often characterized by 
sickness behavior-like phenotypes, may be explained by IL-1β signaling (Maier 2003). There 
is evidence that IL-1β is up regulated throughout the brain after stress exposure (Nguyen, 
Deak et al. 1998; O'Connor, Johnson et al. 2003) and is important in stress-induced 
Hypothalamic-Pituitary-Adrenal (HPA) axis regulatory responses (Goshen, Kreisel et al. 
2008).  
The overall goal of the present study was to examine the role of brain IL-1β in the 
development of stress-enhanced fear learning (SEFL), an animal model of Post-Traumatic 
Stress Disorder (PTSD) developed by Fanselow and colleagues (Rau, DeCola et al. 2005). In 
PTSD, a severe traumatic event leads to debilitating psychological and physiological 
consequences characterized by chronic or exaggerated fear and anxiety (Gill, Saligan et al. 
2009). PTSD affects 7.7 million Americans (NIMH), including up to 17% of combat veterans 
(Richardson, Frueh et al. 2010). However, there is no consistently effective treatment. While 
several animal models of PTSD have been developed (van der Kolk 1987; Yamamoto, 
Morinobu et al. 2009; Kaouane, Porte et al. 2012), the stress-enhanced fear learning 
paradigm (SEFL) is an outstanding model that captures critical components of human PTSD, 
including hyperarousal and hypersensitivity to future fear learning (Rau, DeCola et al. 2005).  
In the SEFL paradigm, rats previously exposed to a severe stressor show an enhanced or 
exaggerated learned fear response to a later mild form of stress in a distinct context, a 
hallmark symptom of PTSD.   
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The present studies test the hypothesis that the severe stressor in SEFL is capable of 
inducing alterations in IL-1β expression in the brain and that this expression is functionally 
relevant to the development of enhanced fear learning. In Experiment 1, we examined the 
time course of IL-1β expression following the severe stressor in SEFL. Our analysis focused 
on the dorsal hippocampus (DH, including the dentate gyrus (DG), CA1, and CA3), 
basolateral amygdala (BLA), and perirhinal cortex (PrhC)  - three regions that have been 
shown to be critical to fear conditioning (Anagnostaras, Gale et al. 2001; Kim, Loucks et al. 
2011; Acheson, Gresack et al. 2012; Kent and Brown 2012). In Experiment 2, we tested 
whether blocking central IL-1β signaling with an infusion of interleukin-1 receptor 
antagonist (IL-1ra) in the 48 hours following the severe stressor prevented the development 
of SEFL. In Experiment 3 we tested whether morphine administration attenuated the 
induction of IL-1β following the severe stressor in SEFL. This third experiment is based 
upon prior studies in our laboratory using this model showing that morphine administered 
after the severe stressor is effective in preventing the development of SEFL (Szczytkowski-
Thomson, Lebonville et al. 2013).  Moreover, clinical studies also show that morphine 
administration in the hours after a combat injury or single event trauma requiring 
hospitalization was associated with a reduced risk of PTSD (Bryant, Creamer et al. 2009; 
Stoddard, Sorrentino et al. 2009; Holbrook, Galarneau et al. 2010; Nixon, Nehmy et al. 2010; 
Melcer, Walker et al. 2014). Thus, in this third experiment, we hypothesize that IL-1β 
signaling is altered by morphine and therefore may be one mechanism through which 
morphine alters SEFL.   
  
CHAPTER II 
METHODS AND MATERIALS 
 
METHODS 
Animals 
Male Sprague-Dawley rats (250-400g, Charles River Laboratories, Raleigh, NC) were 
housed individually under a reversed light-dark (12-hour) cycle with ad libitum access to 
food and water. Animals were handled regularly during a one week acclimation period prior 
to experimentation. All procedures were conducted in accordance with and approval by the 
UNC Institutional Animal Care and Use Committee.  
Experiment 1 - Analysis of IL-1β immunoreactivity and mRNA expression following the 
severe stressor in SEFL  
 
Animals were exposed to only the initial stressor of our typical SEFL model.  The 
SEFL model we employ has been described previously (Szczytkowski-Thomson, Lebonville 
et al. 2013) and is based on the model of Fanselow and colleagues (Rau, DeCola et al. 2005). 
Briefly, in Experiments 1a and 1b, animals were placed into Context A for 90 minutes to 
receive 15 scrambled foot shocks (2 mA, 1s) on a 6-minute variable time schedule. Control 
animals were exposed to Context A for an equivalent amount of time without foot shocks.  
In Experiment 1a brain tissue was processed for immunohistochemical analysis. These 
animals (N = 36, n = 6) were assigned to either a no foot shock group (NS Control) or a foot 
shock group and one of five time points: 0, 6, 24, 48, or 72 hours after the stressor. Animals 
in the NS Control group were sacrificed 24 hours after removal from Context A. This time 
point was chosen for our control group because any changes in IL-1β induced by learning 
  
from mere exposure to a novel context would be evident after 24 hours (Goshen and Yirmiya 
2009). All other animals were exposed to Context A and sacrificed via transcardial perfusion 
at the appropriate times.  
In Experiment 1b brain tissue was processed for quantitative polymerase chain 
reaction (qPCR) analysis of mRNA. These animals (N = 32, n = 8) were assigned to either a 
no foot shock group (NS Control) or a foot shock group and one of three time points, 0, 24, or 
48 hours after the stressor. Again, animals in the NS control group were sacrificed 24 hours 
after Context A exposure and all other animals were sacrificed via cervical dislocation at the 
appropriate times.  
Experiment 2 - Effect of a central infusion of IL-1ra on the development of SEFL  
Surgical Procedures 
 
Animals were surgically implanted with intracerebroventricular (i.c.v.) cannulae. 
Animals were anesthetized with a 1.0 mg/kg intraperitoneal injection of 9:1 (vol:vol) 
ketamine hydrochloride (100 mg/ml) mixed with xylazine (100 mg/ml). Guide cannulae (26 
Gauge, Plastics One, Roanoke, VA) were directed at the right lateral ventricle (AP -0.9 mm, 
ML -1.5 mm, DV -3.4 mm, relative to bregma). Animals were given three weeks for post-
operative recovery. Correct placements were verified and animals with incorrect placement 
were dropped from the analysis.  
Procedures 
Animals (N = 36, n = 9) were assigned to a Context A treatment (foot shock or no foot 
shock) and a drug treatment (IL-1ra or vehicle) and exposed to the SEFL paradigm. The first 
day of the SEFL paradigm is the foot shock treatment in Context A, as described in 
Experiment 1. Context A (BRS/LVE, Laurel, MD; 26.7×24.8×30.7) and Context B (Med 
Associates, St. Albans, VT) were housed in separate rooms and had distinct textile, olfactory, 
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and auditory characteristics, as described previously (Szczytkowski-Thomson, Lebonville et 
al. 2013). Context B was set-up to record the animals’ behavior using a video recording 
system (Sony Video Camera Model HDR-CX150). Seven days after Context A exposure, 
animals were placed into Context B for 30 minutes. On Day 8, animals were placed into 
Context B for a single scrambled foot shock (1mA, 1s) at 3 minutes, 12 seconds.  On days 9, 
10, 15 and 23 (Test Days 1, 2, 7 and 14), animals were placed in Context B for 8 minutes, 32 
seconds and behavior was recorded to measure freezing behavior, a measure of learned fear, 
defined as a lack of all movement except that required for breathing. No animals in any 
group demonstrated freezing behavior to Context B during habituation/prior to the single foot 
shock, suggesting that there was no generalization of fear between contexts. Thus, any 
differences observed between treatment groups would reflect altered learning to the single 
foot shock in Context B. Videos were analyzed by raters blind to treatment condition.  
IL-1ra (GenScript, Piscataway, NJ) was reconstituted in sterile saline (2.5 µg/µl). 
Twenty-four and 48 hours after removal from Context A, animals were microinfused with 4 
μl of either IL-1ra (10 µg) or sterile saline vehicle at a rate of 2 µl/min. Injectors were left in 
place for 4 minutes to allow for diffusion. These time points were based on our earlier 
finding that morphine administration prevents the development of SEFL when administered 
48 hours after, but not immediately after, Context A (Szczytkowski-Thomson, Lebonville et 
al. 2013).  
Experiment 3 - Analysis of IL-1β immunoreactivity following the severe stressor of 
SEFL in combination with morphine treatment  
 
Animals (N = 28, n = 7) were assigned to a Context A treatment (no foot shock or foot 
shock) and to a morphine treatment (morphine or vehicle). As described in Experiment 1, 
animals were only exposed to the initial stressor of the SEFL paradigm. Morphine was 
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obtained from the National Institute on Drug Abuse (NIDA) and dissolved in sterile saline 
(7.5 mg/ml). Immediately, 24, and 48 hours after removal from Context A, animals were 
administered either 7.5 mg/kg morphine or saline vehicle subcutaneously. One hour after the 
final injection, animals were sacrificed via transcardial perfusion. 
Immunohistochemical Analysis  
In Experiments 1a and 3, animals were deeply anesthetized with 9:1 (vol:vol) 
ketamine hydrochloride (100 mg/ml) mixed with xylazine (100 mg/ml) and transcardially 
perfused with cold phosphate buffer (PB; pH = 7.4) followed by 4% paraformaldehyde in 0.1 
M PB. Brains were placed in 30% sucrose for cryoprotection and sliced into 40 µm sections. 
Tissue sections were washed for 15 minutes with 0.1 M PB, and incubated for 30 minutes at 
80°C in sodium citrate (pH = 8.5) for antigen retrieval. Subsequently, sections were 
incubated for 30 minutes with streptavidin and biotin blocks (Vector Laboratories, 
Burlingame, CA, USA) and pre-incubated for 60 minutes with 3% normal goat serum and 
0.3% Triton X-100 in 0.1 M PB. Sections were incubated overnight with rabbit anti-IL-1β 
(1:1000; Abcam, Cambridge, Ma) in 0.1 M PB with 3% normal goat serum and 0.3% 
Tween20.  Similar to Johnson & Kan (Johnson and Kan 2010), sections were then incubated 
for 60 minutes with biotinylated goat anti-rabbit IgG (1:1000, Vector Laboratories, 
Burlingame, CA) in 1% normal goat serum and a streptavidin- Alexafluor488-conjugated 
tertiary antibody (1:1000, Life Technologies, Grand Island, NY) was used for visualization. 
Tissue sections labeled with only secondary and tertiary antibodies were used as secondary 
controls to ensure specificity of our primary antibody. Sections were mounted onto 
SuperFrost Plus slides (Fisher Scientific, Pittsburgh, PA) using Vectashield with DAPI 
hardset mounting medium (Vector Laboratories, Burlingame, CA).  
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Color images were captured through a digital camera (Roper Scientific), mounted on 
an optical microscope (BX-51, Olympus), and positive fluorescence was quantified using 
ImageJ (NIH). Images captured were between -2.76 mm and -4.2 mm relative to bregma 
(Paxinos and Watson, 1998). Three to six sections were analyzed per animal for each brain 
region and values were averaged and expressed as positive stain per 5 µm2. Images were 
normalized to background fluorescence using a manual thresholding procedure such that the 
binary overlay completely covered all positive stain (similar to (Sugama, Takenouchi et al. 
2011)). In addition, the number of IL-1β-positive cells in the all images taken from the 
dentate gyrus of the DH was counted manually. Images with high background that resulted 
from poor perfusion were dropped from the analysis. This decision was made at the time of 
thresholding and was made blind to the treatment condition. All thresholding and counting 
was conducted blind to the treatment condition. Publication images were compiled with 
Adobe Photoshop CS software. Color levels and background were reduced for optimal 
representation with levels and curves tools. Images from all experimental groups were treated 
equally.  
Quantitative Polymerase Chain Reaction (qPCR) analysis  
Following sacrifice, brains were extracted and the hippocampus was immediately 
dissected out on a cold plate. The dorsal third of the hippocampus was stored in 5X (vol/wt) 
RNAlater (Qiagen) and immediately flash frozen. Tissue was processed by the UNC Animal 
Clinical Chemistry and Gene Expression Laboratories according to protocols previously 
reported (Kim, Lee et al. 2002). Briefly, brain tissue was homogenized in RNAlysis buffer 
(PE Biosystems, Foster City, CA) with Ca2 and Mg2- free PB using a Fast Prep 120 mixer 
(QBIOgene, Vista, CA). RNA isolations were purified using the ABI Prism 6700 automated 
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nucleic acid workstation (PE Biosystems) according to the manufacturer’s protocol. Real-
time RT-PCR reactions were performed in the ABI Prism 7700 sequence detector (PE 
Biosystems) in a total volume of 30 µl (10 µl RNA, 20 µl reaction mixture). Each qPCR 
amplification was performed in duplicate: 30 min at 48°C for the RT reaction and 10 min at 
94°C followed by 40 temperature cycles (15 sec at 94°C and 1 min at 60°C). Signal intensity 
was normalized to β-actin as an endogenous control. The nucleotide sequences of the PCR 
primers and fluorogenic probes used for the IL-1β and β-actin genes were as follows: IL-1β 
forward: 5’-GCC TCA AGG GGA AGA ATC TA-3’, reverse: 5’-ATC CAC ACT CTC 
CAG CTG C-3’, probe: 5’-FCT GTG TAA TGA AAG ACG GCA CAC CCA CQ-3’; β-
actin forward: 5’-TGC CTG ACG GTC AGG TCA-3’, reverse: 5’-CAG GAA GGA AGG 
CTG GAA G-3’, probe: 5’-FCA CTA TCG GCA ATG AGC GGT TCC GQ-3’.  
Statistical Analysis 
For Experiments 1a and 1b, positive fluorescence and cell counts were analyzed using 
a one-way ANOVA with treatment group as the between subjects factor. For Experiment 2, a 
2 x 2 ANOVA with Context A treatment and drug treatment as between subjects factors was 
used to analyze baseline freezing behavior. A 2 x 2 x 4 ANOVA with Context A treatment 
and drug treatment as between subjects factors and test day as a within subjects factor was 
used to analyze freezing behavior across test days. Lastly, for Experiment 3, positive 
fluorescence and cell counts were analyzed using a 2 x 2 ANOVA with Context A treatment 
and morphine treatment as between subjects factors. Significant interactions were examined 
using Fisher’s least significant difference (LSD) post-hoc tests.   
  
CHAPTER III  
RESULTS 
 
RESULTS 
Experiment 1: Severe stressor enhances IL-1β immunoreactivity and mRNA expression 
in the dorsal hippocampus but not basolateral amygdala or perirhinal cortex 
 
In Experiment 1a, IL-1β immunoreactivity was significantly enhanced by exposure to 
the severe stressor in a time-sensitive manner such that an increase was observed beginning 6 
hours after the severe stressor and persisted through 72 hours (Figure 1). Severe stress 
significantly enhanced IL-1β immunoreactivity in the dentate gyrus (DG) both in terms of the 
percent area of positive fluorescence, F (5, 25) = 6.472, p < .01, and in terms of IL-1β-
positive cell counts, F (5, 16) = 13.544, p < .01 . LSD post hoc tests revealed that compared 
to the no foot shock group, IL-1β expression was significantly enhanced at 6, 24, 48, and 72 
hours (p < .01). In contrast, IL-1β expression in CA1, CA3, the BLA and the PrhC was not 
altered by the severe stressor at any of the time points (Figure 1).  
In Experiment 1b, exposure to the severe stressor significantly enhanced IL-1β 
mRNA expression in the dorsal hippocampus in a time-dependent manner, F (3, 26) = 6.927, 
p < .001 (Figure 1). LSD post hoc tests revealed that, compared to the no foot shock group, 
IL-1β mRNA expression was significantly enhanced at 48 hours (p < .01). While mRNA and 
protein reflect distinct points of the IL-1 signal, the discrepancy in the time course of the 
effect between Experiments 1a and 1b may reflect the observation in Experiment 1 that the 
effect is specific to the DG. The tissue processed for qPCR included whole DH samples, and 
thus the time course of the effect may be different from the immunohistochemical analysis of 
  
the DH since the CA1/3 did not achieve significance. Still, Experiment 1b further 
confirms an increase in IL-1β on a delayed timeline in the DH following foot shock.  
Experiment 2: IL-1ra prevents the development of stress-enhanced fear learning 
There was no effect of Context A treatment or drug treatment on baseline freezing in 
Context B, indicating no generalization of fear between contexts, F (3, 38) = 1.91, p > .05. A 
2 x 2 x 4 ANOVA revealed a significant main effect of Context A treatment, F (1, 36) = 
11.08, p < .01, and a significant main effect of drug treatment, F (1, 36) = 12.99, p < .01. 
There was also a significant effect of test day, indicating that conditioned fear diminished 
over time, F (3, 34) = 21.76, p < .01. Most interestingly, there was a significant Context A 
treatment by drug treatment interaction, F (1, 36) = 6.497, p < .05. LSD post hoc 
comparisons showed that the animals that received foot shock followed by vehicle exhibited 
significantly more freezing behavior compared to animals that received no foot shock in 
Context A followed by vehicle (p < .01), confirming a significant stress-enhanced fear 
learning effect. The animals that received foot shock in Context A followed by IL-1ra and the 
animals that received no foot shock in Context A followed by IL-1ra did not differ in 
freezing behavior exhibited in Context B, p > .05. Thus, these results show that stress-
enhanced fear learning was prevented by an i.c.v. administration of IL-1ra (Figure 2).  
Experiment 3: Morphine administration attenuates severe stressor-induced IL-1β 
immunoreactivity in the dorsal hippocampus 
 
Severe stress significantly enhanced IL-1β expression within vehicle treated animals 
in the dentate gyrus of the DH, and this enhancement was significantly attenuated in animals 
that received foot shock followed by the morphine treatment (Figure 3). A 2 x 2 ANOVA 
revealed a main effect of Context A treatment, F (1, 19) = 78.164, p < .001, and a main effect 
of morphine treatment, F (1, 19) = 13.651, p < .01. Importantly, there was a significant 
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Context A treatment by morphine treatment interaction, F (1, 19) = 31.050, p < .01. LSD post 
hoc comparisons revealed that animals that received foot shock in Context A followed by 
vehicle treatment exhibited significantly enhanced IL-1β expression compared to animals 
that received no foot shock in Context A followed by vehicle treatment (p < .001), replicating 
the effect observed in Experiment 1a. Animals that received no foot shock in Context A 
followed by morphine treatment were not significantly different from animals that received 
no foot shock in Context A followed by vehicle. However, animals that received foot shock 
in Context A followed by the morphine treatment exhibited significantly less IL-1β 
expression compared to the group that received foot shock in Context A followed by vehicle, 
p < .001. Similar to Experiment 1a, all statistical analyses were confirmed by data obtained 
from counts of IL-1β-positive cells (Figure 3).  
  
CHAPTER IV 
DISCUSSION 
 
The current studies demonstrate for the first time that exposure to a severe stressor 
that is capable of producing a PTSD-like phenotype in rats induces a time-dependent increase 
in IL-1β in the DH. Furthermore, central administration of IL-1ra prevents subsequent effects 
of that stressor, namely, the development of SEFL. Previously our laboratory established that 
morphine following the severe stressor also blocks the development of SEFL (Szczytkowski-
Thomson, Lebonville et al. 2013). Here, we show that the same systemic morphine treatment 
also attenuates stress-induced IL-1β expression in the DH. These studies suggest that 
morphine may act through an IL-1β-dependent mechanism to alter SEFL. Collectively, the 
experiments provide new evidence that the expression of IL-1β in the brain following a 
severe stressor is a critical component of the development of SEFL, a model of PTSD.  
In the present study, IL-1β was detected in three brain regions known to be important 
in PTSD and fear acquisition and expression—the hippocampus, amygdala, and perirhinal 
cortex (Kim, Loucks et al. 2011; Acheson, Gresack et al. 2012). These structures are 
extensively interconnected with multiple pathways involving bidirectional synaptic plasticity 
(Kent and Brown 2012). However, the effect of foot shock on IL-1β levels was observed 
only in the DH, with no change in immunoreactivity observed in the BLA or PrhC. More 
specifically, within the DH, the effect was most pronounced in the DG with much less 
expression that was not statistically altered by foot shock in CA1 and CA3. There may be 
other areas yet to be identified that also play an important role.  For example, the ventral 
  
hippocampus is thought to be important in the emotional and affective component of 
memory (Fanselow and Dong 2010) but it is not known what role IL-1 might have in the 
ventral hippocampus. 
Several cell types are capable of producing IL-1β, and both neurons and glia express 
IL-1 receptors (Yabuuchi, Minami et al. 1994; Zhang, Sun et al. 2010).  In astrocytes, IL-1β 
initiates the formation of IL-1β signaling intermediates, such as IL-1 receptor-associated 
kinase (IRAK; (Ringwood and Li 2008; Flannery and Bowie 2010)) and the subsequent 
activation of p38, extracellular signal-regulated kinase (ERK) and nuclear factor kappa-light-
chain-enhancer of activated B cells (NFkB; (Guasch, Blanco et al. 2007; Huang, Smith et al. 
2011)).  Conversely, in hippocampal neurons, IL-1β activates p38 and ERK, but not NFkB 
(Huang, Smith et al. 2011). It should also be acknowledged that IL-1ra blocks multiple forms 
of IL-1 including IL-1α as well as IL-1β.  The relative contributions of these different forms 
of IL-1 should be considered when determining the cellular sources of IL-1. 
The mechanism through which IL-1β induces alterations in SEFL is not known. 
There are studies showing that neuroinflammation modulates synaptic plasticity in the 
hippocampus by influencing long term potentiation (LTP), a process thought to underlie 
some forms of learning. For example, TNF-α concentrations have been found to influence 
LTP in a dose-dependent manner such that extremely high TNF-α concentrations severely 
inhibited LTP in hippocampal neurons (Tancredi, D'Arcangelo et al. 1992). Furthermore, 
Schneider and colleagues found that tetanic stimulation used to induce LTP induced an 
increase in IL-1β mRNA expression specifically in hippocampal slices (Schneider, Pitossi et 
al. 1998) and that IL-1ra impaired the maintenance of LTP. Similarly, IL-1 receptor knockout 
mice did not exhibit LTP in the dentate gyrus (Avital, Goshen et al. 2003). Thus, there are a 
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number of studies indicating the cytokines are involved in both short- and long-term changes 
in synaptic plasticity. 
Physiological evidence that cytokines influence synaptic plasticity is also supported 
by behavioral evidence that central cytokine signaling influences learning in several 
paradigms, including fear conditioning (Yirmiya and Goshen 2011; Szczytkowski, 
Lebonville et al. 2013). For example, acute administration of either TNF-α or IL-1β and 
chronic administration of interleukin-6 (IL-6) enhanced memory performance in a passive 
avoidance paradigm (Matsuda, Wen et al. 1996; Yirmiya, Winocur et al. 2002; Brennan, 
Beck et al. 2004). Furthermore, there is evidence for an effect of IL-1ra in step-down passive 
avoidance learning, but some report memory improvement (Depino, Alonso et al. 2004)  
while others have reported memory impairment(Yirmiya, Winocur et al. 2002).  Early studies 
have also shown that morphine administration, which we show here to reduce hippocampal 
IL-1β, reduces memory for step down avoidance(Izquierdo 1979).  Thus, it is clear that IL-1β 
can alter learning and memory, but the direction of the effects may depend upon such factors 
as the timing of the administration, the severity of stressor, and the type of learning being 
examined. The present findings are unique in that they begin to address the role of IL-1β in 
the neural plastic changes required to alter future learning, i.e., SEFL. 
The present findings suggest that key neurobiological changes that render the animal 
hypersensitive to future fear learning occur on a delayed timeline, in concert with the 
timeline of some forms of memory consolidation. In support, Kozlovsky and colleagues 
(2012) found a similarly time-sensitive effect in the predator-scent stress paradigm, another 
animal model of PTSD (Kozlovsky, Zohar et al. 2012). An administration of corticotrophin-
releasing hormone receptor antisense oligodeoxynucleotide into the DH 48 hours, but not 
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immediately, after severe stress significantly reduced the prevalence of the extreme 
behavioral response in the elevated plus maze and the acoustic startle response test, which is 
thought to reflect PTSD-like behavior (Kozlovsky, Zohar et al. 2012). This is consistent with 
prior data from our laboratory showing that the 48 hour time point is key (Szczytkowski-
Thomson, Lebonville et al. 2013).  Interestingly, the effect of morphine on the prognosis of 
PTSD in combat veterans was also time-dependent such that the relationship between 
morphine administration and a reduced likelihood of PTSD was strongest when it was 
administered in level 2 care, which occurs not immediately on the battlefield but within 72 
hours of the initial trauma (Melcer, Walker et al. 2014). Frankland and Bontempi suggested a 
model of memory consolidation in which components are integrated in the hippocampus into 
a single memory trace which, over time, becomes consolidated to cortical structures and 
integrated with other experiences (termed systems consolidation) (Frankland and Bontempi 
2005). One hypothesis is that SEFL (and PTSD)  is (are) driven by an alteration in the later 
phases of memory consolidation following the trauma that results in the loss of contextual 
detail and renders the animal hypersensitive to future fear learning.   
The present studies do not test whether morphine or IL-1ra impair contextual fear 
learning to Context A. We cannot assume that manipulations that attenuate SEFL, such as IL-
1ra or morphine, also impair memory for Context A. Fanselow and colleagues (2005) 
showed that contextual fear learning to the context where the initial severe shock occurs is 
not critical to the expression of SEFL. They found that eliminating fear learning to Context A 
and extinction of Context A did not affect the expression of SEFL in Context B (Rau, 
DeCola et al. 2005).  Taken together, it would be interesting to know how blocking IL-1 
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influences fear learning to Context A and further whether IL-1β expression is directly 
involved in the learning/enhanced learning to the subsequent foot shock in Context B.  
PTSD is a prevalent problem in the United States with severe fiscal and emotional 
costs to society. The current findings provide strong evidence that the correlation between 
psychopathology and inflammatory dysregulation (e.g., (Bai, Su et al. 2014; Stepanichev, 
Dygalo et al. 2014) is important in behavioral outcomes. Moreover, Melcer and colleagues 
found that susceptibility to PTSD was related to Traumatic Brain Injury (TBI) severity in 
combat veterans (Melcer, Walker et al. 2014), further suggesting that central inflammation is 
related to the development of PTSD. The current studies show that altering central immune 
signaling has a direct causal effect on the development of a PTSD-like phenotype in rats. 
Further, we provide evidence that morphine, a treatment known to reduce the development of 
PTSD and SEFL, may act through an IL-1β-dependent mechanism, providing an exciting 
new target for the development of treatments for PTSD.  
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Figure 1. Severe stress induced IL-1β in the dorsal hippocampus. Representative images 
(20x) of IL-1β (green) in the dorsal hippocampus from animals in each of the six groups are 
shown on the left. The top right panel shows ImageJ analysis of positive fluorescence stain 
(top right) in the dentate gyrus, CA1, CA3, basolateral amygdala and perirhinal cortex. IL-1β 
immunoreactivity was significantly enhanced at 6 hours after (but not immediately after) 
severe stress only in the dentate gyrus of the dorsal hippocampus. This enhancement 
persisted through 72 hours (*p < .05 compared to NS control). qPCR analysis of mRNA 
expression confirmed the IL-1β increase in the dorsal hippocampus that we observed with 
immunohistochemistry (bottom right). IL-1β mRNA was enhanced at 48 hours following 
severe stress (*p < .05 compared to NS control). Further, IL-1β- positive cells were also 
counted in the dentate gyrus of the dorsal hippocampus (bottom right) and the same pattern 
was confirmed.  (*p < .05 compared to 0 h). Error bars indicate SEM.  
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Figure 2. IL-1ra prevents the development of SEFL. IL-1ra infusion (i.c.v., 10 µg at 24 and 
48 hours after removal from Context A) significantly reduced conditioned freezing behavior 
in Context B across test days. There were no significant differences between groups at 
baseline. Within the vehicle-treated groups, foot shock in Context A (open squares) 
significantly enhanced freezing behavior in Context B compared to animals that did not 
receive foot shock in Context A (open circles), demonstrating an SEFL effect. There was no 
effect of IL-1ra in the group that did not receive foot shock in Context A (closed circles). 
Most importantly, animals that received foot shock in Context A followed by IL-1ra infusion 
(closed squares) did not differ from the groups that did not receive foot shock in Context A. 
Error bars indicate SEM.  
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Figure 3. Morphine attenuates stress-induced IL-1β in the dorsal hippocampus. 
Representative images (20x) of IL-1β (green) in the dentate gyrus of the dorsal hippocampus 
from animals in each of the four groups are shown in (a). ImageJ analysis of positive 
fluorescence stain (b) revealed that in vehicle treated animals (NS/Veh and Shock/Veh), foot 
shock significantly enhanced IL-1β; however, morphine administration suppressed the 
induction of IL-1β in animals that received foot shock followed by morphine treatment 
(Shock/M). IL-1β- positive cells were also counted in the dentate gyrus of the dorsal 
hippocampus (c) and the same pattern was confirmed.  (* greater than NS/Veh, p < .05; † 
greater than Shock/M, p < .05). Error bars indicate SEM.  
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